vs
Side-by-side financial comparison of CHIMERA INVESTMENT CORP (CIM) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $66.2M, roughly 1.1× CHIMERA INVESTMENT CORP). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 0.5%). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 0.8%).
Chimera Investment Corp is a US-based real estate investment trust (REIT) primarily investing in residential mortgage-backed securities, residential and commercial mortgage loans, and other real estate-related financial assets. It delivers sustainable risk-adjusted returns for shareholders via regular dividend distributions from its investment portfolio.
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
CIM vs PBYI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $66.2M | $75.5M |
| Net Profit | $28.3M | — |
| Gross Margin | — | 69.3% |
| Operating Margin | 42.6% | 22.7% |
| Net Margin | 42.8% | — |
| Revenue YoY | 0.5% | 27.7% |
| Net Profit YoY | 119.3% | — |
| EPS (diluted) | $0.05 | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $66.2M | $75.5M | ||
| Q3 25 | $65.0M | $54.5M | ||
| Q2 25 | $66.0M | $52.4M | ||
| Q1 25 | $69.2M | $46.0M | ||
| Q4 24 | $65.8M | $59.1M | ||
| Q3 24 | $66.5M | $80.5M | ||
| Q2 24 | $67.3M | $47.1M | ||
| Q1 24 | $65.1M | $43.8M |
| Q4 25 | $28.3M | — | ||
| Q3 25 | $-580.0K | $8.8M | ||
| Q2 25 | $35.5M | $5.9M | ||
| Q1 25 | $167.3M | $3.0M | ||
| Q4 24 | $-146.5M | — | ||
| Q3 24 | $136.5M | $20.3M | ||
| Q2 24 | $56.7M | $-4.5M | ||
| Q1 24 | $129.5M | $-4.8M |
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 75.5% |
| Q4 25 | 42.6% | 22.7% | ||
| Q3 25 | -0.5% | 17.6% | ||
| Q2 25 | 54.3% | 12.7% | ||
| Q1 25 | — | 8.7% | ||
| Q4 24 | -222.6% | 22.6% | ||
| Q3 24 | — | 27.4% | ||
| Q2 24 | 84.2% | -4.6% | ||
| Q1 24 | — | -5.3% |
| Q4 25 | 42.8% | — | ||
| Q3 25 | -0.9% | 16.2% | ||
| Q2 25 | 53.7% | 11.2% | ||
| Q1 25 | 241.7% | 6.5% | ||
| Q4 24 | -222.6% | — | ||
| Q3 24 | 205.4% | 25.2% | ||
| Q2 24 | 84.2% | -9.6% | ||
| Q1 24 | 198.8% | -11.0% |
| Q4 25 | $0.05 | $0.26 | ||
| Q3 25 | $-0.27 | $0.17 | ||
| Q2 25 | $0.17 | $0.12 | ||
| Q1 25 | $1.77 | $0.06 | ||
| Q4 24 | $-2.06 | $0.40 | ||
| Q3 24 | $1.39 | $0.41 | ||
| Q2 24 | $0.41 | $-0.09 | ||
| Q1 24 | $1.36 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $278.6M | $97.5M |
| Total DebtLower is stronger | $251.5M | $22.7M |
| Stockholders' EquityBook value | $2.6B | $130.3M |
| Total Assets | $15.8B | $216.3M |
| Debt / EquityLower = less leverage | 0.10× | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $278.6M | $97.5M | ||
| Q3 25 | $491.5M | $94.4M | ||
| Q2 25 | $250.2M | $96.0M | ||
| Q1 25 | $253.3M | $93.2M | ||
| Q4 24 | $84.0M | $101.0M | ||
| Q3 24 | $97.3M | $96.7M | ||
| Q2 24 | $162.3M | $96.8M | ||
| Q1 24 | $169.0M | $107.2M |
| Q4 25 | $251.5M | $22.7M | ||
| Q3 25 | $251.0M | $34.0M | ||
| Q2 25 | $135.2M | $45.3M | ||
| Q1 25 | $134.9M | $56.7M | ||
| Q4 24 | $134.6M | $68.0M | ||
| Q3 24 | $134.4M | $79.3M | ||
| Q2 24 | $62.4M | $90.7M | ||
| Q1 24 | — | $102.0M |
| Q4 25 | $2.6B | $130.3M | ||
| Q3 25 | $2.6B | $115.3M | ||
| Q2 25 | $2.6B | $104.7M | ||
| Q1 25 | $2.6B | $97.1M | ||
| Q4 24 | $2.5B | $92.1M | ||
| Q3 24 | $2.7B | $71.1M | ||
| Q2 24 | $2.6B | $48.5M | ||
| Q1 24 | $2.6B | $51.0M |
| Q4 25 | $15.8B | $216.3M | ||
| Q3 25 | $15.1B | $202.9M | ||
| Q2 25 | $14.9B | $194.9M | ||
| Q1 25 | $13.2B | $196.2M | ||
| Q4 24 | $13.1B | $213.3M | ||
| Q3 24 | $13.7B | $220.7M | ||
| Q2 24 | $13.1B | $205.0M | ||
| Q1 24 | $12.5B | $214.1M |
| Q4 25 | 0.10× | 0.17× | ||
| Q3 25 | 0.10× | 0.30× | ||
| Q2 25 | 0.05× | 0.43× | ||
| Q1 25 | 0.05× | 0.58× | ||
| Q4 24 | 0.05× | 0.74× | ||
| Q3 24 | 0.05× | 1.12× | ||
| Q2 24 | 0.02× | 1.87× | ||
| Q1 24 | — | 2.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-248.9M | $14.4M |
| Free Cash FlowOCF − Capex | — | $14.4M |
| FCF MarginFCF / Revenue | — | 19.1% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | -8.78× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-248.9M | $14.4M | ||
| Q3 25 | $-137.5M | $9.7M | ||
| Q2 25 | $-7.4M | $14.1M | ||
| Q1 25 | $48.8M | $3.6M | ||
| Q4 24 | $205.7M | $15.6M | ||
| Q3 24 | $41.4M | $11.0M | ||
| Q2 24 | $69.0M | $1.0M | ||
| Q1 24 | $57.3M | $11.2M |
| Q4 25 | — | $14.4M | ||
| Q3 25 | — | $9.7M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | — | $11.0M | ||
| Q2 24 | — | $1.0M | ||
| Q1 24 | — | — |
| Q4 25 | — | 19.1% | ||
| Q3 25 | — | 17.7% | ||
| Q2 25 | — | 26.8% | ||
| Q1 25 | — | 7.7% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | -8.78× | — | ||
| Q3 25 | — | 1.10× | ||
| Q2 25 | -0.21× | 2.41× | ||
| Q1 25 | 0.29× | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.30× | 0.54× | ||
| Q2 24 | 1.22× | — | ||
| Q1 24 | 0.44× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
